Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey

被引：57

作者：

Wedgeworth, E. ^{[1
]}

Glover, M. ^{[3
]}

Irvine, A. D. ^{[4
,5
]}

Neri, I. ^{[6
]}

Baselga, E. ^{[7
]}

Clayton, T. H. ^{[8
]}

Beattie, P. E. ^{[9
]}

Bjerre, J. V. ^{[10
]}

Burrows, N. P. ^{[12
]}

Foelster-Holst, R. ^{[13
]}

Hedelund, L. ^{[11
]}

Hernandez-Martin, A. ^{[14
]}

Audrain, H. ^{[15
]}

Bhate, K. ^{[16
]}

Brown, S. J. ^{[17
]}

Baryschpolec, S. ^{[18
]}

Darne, S. ^{[19
]}

Durack, A. ^{[12
]}

Dvorakova, V. ^{[4
,5
]}

Gach, J. ^{[21
]}

Goldstraw, N. ^{[22
]}

Goodyear, H. ^{[23
]}

Grabczynska, S. ^{[24
]}

Greenblatt, D. ^{[22
]}

Halpern, J. ^{[25
]}

Hearn, R. M. R. ^{[17
]}

Hoey, S. ^{[26
]}

Hughes, B. ^{[18
]}

Jayaraj, R. ^{[20
]}

Johansson, E. K. ^{[27
]}

Lam, M. ^{[16
]}

Leech, S. ^{[28
]}

O'Regan, G. M. ^{[4
,5
]}

Morrison, D. ^{[2
]}

Porter, W. ^{[29
]}

Ramesh, R. ^{[25
]}

Schill, T. ^{[30
,31
]}

Shaw, L. ^{[15
]}

Taylor, A. E. M. ^{[28
]}

Taylor, R. ^{[32
]}

Thomson, J. ^{[1
]}

Tiffin, P. ^{[33
]}

Tsakok, M. ^{[34
]}

Janmohamed, S. R. ^{[35
]}

Laguda, B. ^{[36
]}

McPherson, T. ^{[34
]}

Oranje, A. P. ^{[37
]}

Patrizi, A. ^{[6
]}

Ravenscroft, J. C. ^{[16
]}

Shahidullah, H. ^{[38
]}

机构：

[1] Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, Dept Paediat Dermatol, London, England

[2] Guys & St Thomas Hosp NHS Fdn Trust, Dept Paediat Ophthalmol, London, England

[3] Great Ormond St Hosp NHS Fdn Trust, Dept Paediat Dermatol, London, England

[4] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland

[5] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland

[6] Univ Bologna, S Orsola Malpighi Hosp, Dermatol Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy

[7] Hosp Santa Creu & Sant Pau, Dept Dermatol, Pediat Dermatol Unit, Barcelona, Spain

[8] Royal Manchester Childrens Hosp, Dept Paediat Dermatol, Manchester M27 1HA, Lancs, England

[9] Royal Hosp Sick Children, Dept Paediat Dermatol, Glasgow G3 8SJ, Lanark, Scotland

[10] Aarhus Univ Hosp, Dept Paediat, DK-8000 Aarhus, Denmark

[11] Aarhus Univ Hosp, Dept Dermatol, DK-8000 Aarhus, Denmark

[12] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Dermatol, Cambridge, England

[13] Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel, Kiel, Germany

[14] Hosp Infantil Nino Jesus, Dept Dermatol, Madrid, Spain

[15] Univ Hosp Bristol NHS Fdn Trust, Dept Paediat Dermatol, Bristol, Avon, England

[16] Nottingham Childrens Hosp, Dept Paediat Dermatol, Nottingham, England

[17] Univ Dundee, Ninewells Hosp & Med Sch, Dept Dermatol, Dundee DD1 9SY, Scotland

[18] Portsmouth Hosp NHS Trust, Dept Dermatol, Portsmouth, Hants, England

[19] South Tees Hosp NHS Fdn Trust, Dept Dermatol, Middlesbrough, Cleveland, England

[20] South Tees Hosp NHS Fdn Trust, Dept Paediat, Middlesbrough, Cleveland, England

[21] Univ Hosp Coventry & Warwickshire, Dept Dermatol, Coventry, W Midlands, England

[22] St Georges Univ Hosp NHS Fdn Trust, Dept Dermatol, London, England

[23] Heart England NHS Fdn Trust, Dept Paediat Dermatol, Birmingham, W Midlands, England

[24] Buckinghamshire Healthcare NHS Trust, Dept Dermatol, Amersham, England

[25] Sandwell & West Birmingham Hosp NHS Trust, Dept Dermatol, Birmingham, W Midlands, England

[26] Royal Victoria Hosp, Dept Dermatol, Belfast BT12 6BA, Antrim, North Ireland

[27] Soder Sjukhuset, Dermatol & Venereal Clin, Stockholm, Sweden

[28] Newcastle Tyne Hosp NHS Fdn Trust, Dept Paediat Dermatol, Newcastle, NSW, Australia

[29] Gloucestershire Hosp NHS Fdn Trust, Dept Paediat Dermatol, Gloucester, England

[30] Catholic Childrens Hosp Wilhelmstift, Dept Paediat, Hamburg, Germany

[31] Catholic Childrens Hosp Wilhelmstift, Dept Paediat Dermatol, Hamburg, Germany

[32] York Teaching Hosp NHS Fdn Trust, Dept Ophthalmol, York, N Yorkshire, England

[33] City Hosp Sunderland NHS Fdn Trust, Dept Ophthalmol, Sunderland, England

[34] Oxford Univ Hosp, Dept Dermatol, Oxford, England

[35] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Dermatol, Laarbeeklan 101, B-1090 Brussels, Belgium

[36] Chelsea & Westminster Hosp NHS Fdn Trust, Dept Paediat Dermatol, London, England

[37] Dermicis Alkmaar & Fdn Network Pediat Dermatol Ro, Dept Dermatol Paediat Dermatol & Hair, Rotterdam, Netherlands

[38] Derby NHS Fdn Trust, Dept Dermatol, Derby, England

[39] Lund Univ, Inst Clin Res Malmo, Skane Univ Hosp, Dept Dermatol, Malmo, Sweden

[40] Karolinska Inst, Dept Med Solna, Dermatol Unit, Stockholm, Sweden

[41] Karolinska Univ Hosp, Stockholm, Sweden

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2016年 / 174卷 / 03期

基金：

美国国家卫生研究院;

关键词：

ORAL PROPRANOLOL; CLINICAL CHARACTERISTICS; PROLIFERATION PHASE; CONTROLLED-TRIAL; THERAPY;

D O I：

10.1111/bjd.14233

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs). Anecdotally, prescribing practice differs widely between centres. Objectives The Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce was founded to establish patterns of use of propranolol in IHs. Methods Participating centres entered data on all of their patients who had completed treatment with oral propranolol for IHs, using an online data capture tool. Results The study cohort comprised 1097 children from 39 centres in eight European countries. 76.1% were female and 92.8% had a focal IH, with the remainder showing a segmental, multifocal or indeterminate pattern. The main indications for treatment were periocular location (29.3%), risk of cosmetic disfigurement (21.1%) and ulceration and bleeding (20.6%). In total 69.2% of patients were titrated up to a maintenance regimen, which consisted of 2 mg kg(-1) per day (85.8%) in the majority of cases. 91.4% of patients had an excellent or good response to treatment. Rebound growth occurred in 14.1% upon stopping, of whom 53.9% were restarted and treatment response was recaptured in 91.6% of cases. While there was no significant difference in the treatment response, comparing a daily maintenance dose of < 2 mg kg(-1) vs. 2 mg kg(-1) vs. > 2 mg kg(-1), the risk of adverse events was significantly higher: odds ratio (OR) 1 vs. adjusted OR 0.70, 95% confidence interval (CI) 0.331.50, P = 0.36 vs. OR 2.38, 95% CI 1.04-5.46, P = 0.04, Ptrend < 0.001. Conclusions The PITCH survey summarizes the use of oral propranolol across 39 European centres, in a variety of IH phases, and could be used to inform treatment guidelines and the design of an interventional study.

引用

页码：594 / 601

页数：8

共 50 条

[21] Efficacy of propranolol treatment in infantile hepatic haemangioma
Yang, Kaiying
Peng, Suhua
Chen, Linwen
Chen, Siyuan
Ji, Yi
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2019, 55 (10) : 1194 - 1200
[22] Cardiac screening in patients with infantile hemangiomas before propranolol treatment
Turan, Ozlem
Koker, Sultan Aydin
CUKUROVA MEDICAL JOURNAL, 2023, 48 (03): : 1000 - 1006
[23] Recent Advances in Propranolol Hydrochloride Formulations for the Treatment of Infantile Hemangiomas
Ren, Lin
Xu, Xiaowen
Liu, Xianbin
Ning, Hong
Ding, Qian
Yang, Min
Liang, Tiantian
DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 1163 - 1183
[24] Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas
Polites, Stephanie F.
Rodrigue, Bentley B.
Chute, Carol
Hammill, Adrienne
Dasgupta, Roshni
PEDIATRIC BLOOD & CANCER, 2018, 65 (10)
[25] Treatment of Infantile Capillary Hemangioma of the Eyelid with Systemic Propranolol
Vassallo, Patrizia
Forte, Raimondo
Di Mezza, Antonio
Magli, Adriano
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (01) : 165 - 170
[26] Propranolol Treatment in Infantile Hemangiomas: A Single Center Experience
Karatekin, Seyma
Aycicek, Ali
Gundogdu, Muge
Aldemir, Huseyin
JOURNAL OF CHILD - COCUK DERGISI, 2023, 23 (01): : 84 - 88
[27] Preliminary results of propranolol treatment for patients with infantile hemangioma
Corapcioglu, Funda
Buyukkapu-Bay, Sema
Binnetoglu, Koksal
Babaoglu, Abdulkadir
Anik, Yonca
Tugay, Melih
TURKISH JOURNAL OF PEDIATRICS, 2011, 53 (02) : 137 - 141
[28] Oral propranolol: an effective, safe treatment for infantile hemangiomas
Zaher, Hesham
Rasheed, Hoda
Hegazy, Rehab A.
Hegazy, Ranya A.
Abdelhalim, Dalia M.
Gawdat, Heba I.
EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (04) : 558 - 563
[29] Liposomal propranolol for treatment of infantile hemangioma at compounding pharmacies
Nifli, Antigone
Liakopoulou, Aggeliki
Mourelatou, Elena
Avgoustakis, Konstantinos
Hatziantoniou, Sophia
JOURNAL OF LIPOSOME RESEARCH, 2024, 34 (04) : 523 - 534
[30] Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
Prasad, Arun
Sinha, Amit Kumar
Kumar, Bindey
Prasad, Abhiranjan
Kumari, Manju
PAN AFRICAN MEDICAL JOURNAL, 2019, 32

← 1 2 3 4 5 →